Lupin has informed that it enclosed a Press Release regarding receipt of tentative approval from the US FDA for the Company’s Abbreviated New Drug Application, Valbenazine Capsules, 40 mg, 60 mg, and 80 mg, to market a generic equivalent of Ingrezza Capsules, 40 mg, 60 mg, and 80 mg, of Neurocrine Biosciences, Inc.
The above information is a part of company’s filings submitted to BSE.